ERCP in RYGB-patients: One size fits all?

The obesity epidemic is among the world’s most devastating health problems, outnumbering starvation, and even the COVID-19 pandemic in morbidity and mortality. Although weight loss efforts through lifestyle modifications are generally recommended, and do add to the necessary armamentarium, they are by themselves usually insufficient. Conversely, bariatric surgery is well established as an effective treatment, and among the alternative methods, Roux-en-Y gastric bypass (RYGB) is still widely popular, given the current efficacy and acceptable side-effect profile [1].

Publikationsverlauf

Artikel online veröffentlicht:
16. Juni 2020

• References

• 1 Morales-Maza J, Rodriguez-Quintero JH, Sanchez-Morales GE. et al. Laparoscopic Roux-en-Y gastric bypass in the treatment of obesity: evidence based update through randomized clinical trials and meta-analyses. Il Giornale di chirurgia 2020; 41: 5-17
• 2 Blom-Hogestol IK, Stubhaug A, Kristinsson JA. et al. Diagnosis and treatment of chronic abdominal pain 5 years after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2018; 14: 1544-1551
• 3 Kedia P, Sharaiha RZ, Kumta NA. et al. Internal EUS-directed transgastric ERCP (EDGE): game over. Gastroenterology 2014; 147: 566-568
• 4 Dhindsa BS, Dhaliwal A, Mohan BP. et al. EDGE in Roux-en-Y gastric bypass: How does it compare to laparoscopy-assisted and balloon enteroscopy ERCP: a systematic review and meta-analysis. Endosc Int Open 2020; 8: E163-E171
• 5 Kochhar G, Mohy-ud-din N, Grover A. et al. EUS Directed transgastric endoscopic retrograde cholangio-pancreatography versus laparoscopic-assisted ERCP versus deep enteroscopy assisted ERCP. Endosc Int Open 2020; 08: E877-E882
• 6 Krafft MR, Hsueh W, James TW. et al. The EDGI new take on EDGE: EUS-directed transgastric intervention (EDGI), other than ERCP, for Roux-en-Y gastric bypass anatomy: a multicenter study. Endosc Int Open 2019; 7: E1231-E1240